1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,100 | 6,350 | 29.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| Di | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION ... | - | HKEx | ||
| 20.01. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION FOR A PHASE 1B/2 CLINICAL TRIAL OF HLX701 (RECOMBINANT HUMAN SIRPA - IGG4 ... | - | HKEx | ||
| 19.01. | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION OF THE COMPANY | 1 | HKEx | ||
| 16.01. | Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026 | 196 | PR Newswire | SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held in San Francisco, the United States, from January 12 to 15. On January... ► Artikel lesen | |
| 16.01. | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - ISSUANCE OF THE FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY | 2 | HKEx | ||
| 13.01. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION (BLA) FOR HANBEITAI (BEVACIZUMAB INJECTION) HAS BEEN ACCEPTED BY THE UNITED STATES ... | 1 | HKEx | ||
| 31.12.25 | HENLIUS (02696): POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, 31 DECEMBER 2025 | 3 | HKEx | ||
| 31.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS | 1 | HKEx | ||
| 29.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 AND ... | 4 | HKEx | ||
| 23.12.25 | Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026 | 722 | PR Newswire | SHANGHAI, Dec. 23, 2025 /PRNewswire/ -- The 44th J.P. Morgan Healthcare Conference will take place from January 12 to 15, 2026, in San Francisco, USA. Dr. Jason Zhu, Executive Director and... ► Artikel lesen | |
| 19.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF NIVOLUMAB BIOSIMILAR HLX18 (RECOMBINANT ... | 4 | HKEx | ||
| 12.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY FOR NEO-/ ... | 1 | HKEx | ||
| 09.12.25 | Alligator Bioscience Comments on Henlius Receiving Regulatory Approval in China to Initiate Phase 2/3 Trials of HLX22 in HER2-Positive Breast Cancer | 356 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 9, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) today comments on the announcement by Shanghai Henlius Biotech, Inc. that applications for Phase... ► Artikel lesen | |
| 09.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - APPLICATIONS FOR PHASE 2/3 CLINICAL TRIALS OF HLX22 (RECOMBINANT HUMANISED ANTI-HER2 MONOCLONAL ANTIBODY INJECTION) ... | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): PROXY FORM FOR THE 2025 FOURTH EXTRAORDINARY GENERAL MEETING TO BE HELD ON 31 DECEMBER 2025 (OR ANY ADJOURNMENT THEREOF) | - | HKEx | ||
| 03.12.25 | HENLIUS (02696): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF THE SINOPHARM DISTRIBUTION COLLABORATION | 1 | HKEx | ||
| 03.12.25 | HENLIUS (02696): CONNECTED TRANSACTION AND CONTINUING CONNECTED TRANSACTIONS - COLLABORATION AGREEMENTS WITH AVANC PHARMA FOR FOVINACICLIB CITRATE CAPSULES | - | HKEx | ||
| 02.12.25 | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY ... | 2 | HKEx |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,335 | -0,85 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen von "Buy" auf "Hold" abgestuft. Das Kursziel erhöhte Analyst Jan Koch in einer am Donnerstag vorliegenden Studie aber von 52 auf 54 US-Dollar.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,400 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,650 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 69,98 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| IMMUNOVANT | 26,450 | +1,46 % | Immunovant Inc.: Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 | ||
| ALUMIS | 26,840 | -3,10 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 11,160 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,880 | +1,25 % | Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? | ||
| STRUCTURE THERAPEUTICS | 87,15 | -2,19 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| IMMUNOME | 25,070 | +1,27 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 10,310 | +1,78 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,56 | +0,12 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BIONTECH | 97,75 | +0,62 % | Moderna erneut mit Kurssprung, auch BioNTech gibt Gas - was ist da los? | Die Aktie von Moderna ging am Mittwoch mit einem Plus von fast 16 Prozent aus dem Handel. Damit gelang der Sprung auf ein neues 52-Wochen-Hoch. Auch die Aktie des deutschen Konkurrenten BioNTech verzeichnete... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,68 | +1,40 % | Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 | ||
| RECURSION PHARMACEUTICALS | 4,320 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
Das Unternehmen SHANGHAI HENLIUS BIOTECH INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,63 % bei einem Aktienkurs von 6,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.